Papers by Luiz José de Oliveira Júnior
Therapy response assessment is a critical step in cancer management, leading clinicians to optimi... more Therapy response assessment is a critical step in cancer management, leading clinicians to optimize the use of therapeutic options during the course of the disease. Imaging is a pivotal biomarker for therapy response evaluation in oncology and has gained wider use through the development of reproducible data-based guidelines, of which the Response Evaluation Criteria in Solid Tumors is the most successful example. Disease-specific criteria have also been proposed, and the Prostate Cancer Working Group 3 criteria are the mainstay for prostate cancer (PC). However, conventional imaging evaluation in metastatic prostate cancer has several limitations, including (a) the inability to detect small-volume disease, (b) the high prevalence of bone (nonmeasurable) lesions at imaging, and (c) the established role of serum prostate-specific antigen (PSA) levels as the biomarker of choice for response assessment and disease progression. In addition, there are an increasing number of newer treatment options with various effects on imaging features. Prostate-specific membrane antigen (PSMA) PET has improved patient selection for newer treatments, such as metastasis-directed therapy (MDT) or radionuclide therapy. The role of PSMA PET in response assessment for many metastatic PC therapeutic options (MDT, androgen deprivation therapy, chemotherapy, radionuclide therapy, and immunotherapy) is an evolving issue, with emerging data showing good correlation with PSA levels and clinical outcome. However, there are specific implications of each therapy (especially androgen deprivation therapy and immunotherapy) on PSMA expression by PC cells, leading to potential pitfalls and inaccuracies that must be known by radiologists. Despite some limitations, PSMA PET is addressing gaps left by conventional imaging methods (eg, CT and bone scanning) and nonimaging biomarkers (PSA levels) in metastatic PC therapy response assessment, a role that can be improved with advances like refinement of interpretation criteria and whole-body tumor burden quantification. © RSNA, 2020 • Abbreviations: ADT = androgen deprivation therapy, CRPC = castration-resistant PC, FDG = fluorine 18 fluorodeoxyglucose, ISUP = International Society of Urological Pathology, MDT = metastasis-directed therapy, PC = prostate cancer, PCWG3 = Prostate Cancer Working Group 3, PSA = prostate-specific antigen, PSMA = prostate-specific membrane antigen, RECIST = Response Evaluation Criteria in Solid Tumors, SBRT = stereotactic body radiation therapy, SUV max = maximum standardized uptake value RadioGraphics 2020; 40:0000-0000 https://doi.
Uploads
Papers by Luiz José de Oliveira Júnior